?立即早期癌基因BRLF1/鼻咽癌基因抗体Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
Expression of the Epstein-Barr virus (EBV) immediate-early (IE) protein BRLF1 induces the lytic form of viral replication in most EBV-positive cell lines. BRLF1 is a transcriptional activator that binds directly to a GC-rich motif present in some EBV lytic gene promoters.立即早期癌基因BRLF1/鼻咽癌基因抗体 However, BRLF1 activates transcription of the other IE protein, BZLF1, through an indirect mechanism which we previously showed to require activation of the stress mitogen-activated protein kinases. Here we demonstrate that BRLF1 activates phosphatidylinositol-3 (PI3) kinase signaling in host cells. We show that the specific PI3 kinase inhibitor, LY294002, completely abrogates the ability of a BRLF1 adenovirus vector to induce the lytic form of EBV infection, while not affecting lytic infection induced by a BZLF1 adenovirus vector. Furthermore,立即早期癌基因BRLF1/鼻咽癌基因抗体 we demonstrate that the requirement for PI3 kinase activation in BRLF1-induced transcriptional activation is promoter dependent. BRLF1 activation of the SM early promoter (which occurs through a direct binding mechanism) does not require PI3 kinase activation, whereas activation of the IE BZLF1 and early BMRF1 promoters requires PI3 kinase activation. Thus, there are clearly two separate mechanisms by which BRLF1 induces transcriptional activation.
Also known as:
立即早期癌基因BRLF1/鼻咽癌基因抗体Replication and transcription activator; Rta; Immediate-early protein Rta; HHV4tp2_gp33; BRLF1 [Human herpesvirus 4 type 2].
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: HHV4tp2.
●
Immunogen: KLH conjugated synthetic peptide derived from human herpesvirus 4 type 2 BRLF1.
●
立即早期癌基因BRLF1/鼻咽癌基因抗体Predicted Molecular Weight: 66.5kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
kl585Hu01细胞周期素D1(CCND1)多克隆抗体Polyclonal Antibody to Cyclin D1 (CCND1)
kl585Mu01细胞周期素D1(CCND1)多克隆抗体Polyclonal Antibody to Cyclin D1 (CCND1)
kl585Ra01细胞周期素D1(CCND1)多克隆抗体Polyclonal Antibody to Cyclin D1 (CCND1)
kl586Hu01细胞周期素D2(CCND2)多克隆抗体Polyclonal Antibody to Cyclin D2 (CCND2)
kl588Hu01M2-型丙酮酸激酶(PKM2)多克隆抗体Polyclonal Antibody to Pyruvate Kinase, Muscle (PKM2)
kl588Mu01M2-型丙酮酸激酶(PKM2)多克隆抗体Polyclonal Antibody to Pyruvate Kinase, Muscle (PKM2)
kl588Ra01M2-型丙酮酸激酶(PKM2)多克隆抗体Polyclonal Antibody to Pyruvate Kinase, Muscle (PKM2)
kl589Hu01血红素氧合酶2(HO2)多克隆抗体Polyclonal Antibody to Heme Oxygenase 2, Decycling (HO2)
kl589Ra01血红素氧合酶2(HO2)多克隆抗体Polyclonal Antibody to Heme Oxygenase 2, Decycling (HO2)
kl593Hu01肌原纤蛋白1(FBN1)多克隆抗体Polyclonal Antibody to Fibrillin 1 (FBN1)
kl593Ra01肌原纤蛋白1(FBN1)多克隆抗体Polyclonal Antibody to Fibrillin 1 (FBN1)
kl598Ra01微粒体谷胱甘肽S转移酶2(MGST2)多克隆抗体Polyclonal Antibody to Microsomal Glutathione S Transferase 2 (MGST2)
kl599Mu01颗粒酶A(GZMA)多克隆抗体Polyclonal Antibody to Granzyme A (GZMA)
kl600Hu01颗粒酶B(GZMB)多克隆抗体Polyclonal Antibody to Granzyme B (GZMB)
kl600Mu01颗粒酶B(GZMB)多克隆抗体Polyclonal Antibody to Granzyme B (GZMB)
kl600Ra01颗粒酶B(GZMB)多克隆抗体Polyclonal Antibody to Granzyme B (GZMB)
kl601Bo01髓过氧化物酶(MPO)多克隆抗体Polyclonal Antibody to Myeloperoxidase (MPO)
kl601Eq01髓过氧化物酶(MPO)多克隆抗体Polyclonal Antibody to Myeloperoxidase (MPO)
kl601Po01髓过氧化物酶(MPO)多克隆抗体Polyclonal Antibody to Myeloperoxidase (MPO)
kl602Hu01过氧化物酶体生物合成因子2(PEX2)多克隆抗体Polyclonal Antibody to Peroxisomal Biogenesis Factor 2 (PEX2)
kl602Mu01过氧化物酶体生物合成因子2(PEX2)多克隆抗体Polyclonal Antibody to Peroxisomal Biogenesis Factor 2 (PEX2)
kl602Ra01过氧化物酶体生物合成因子2(PEX2)多克隆抗体Polyclonal Antibody to Peroxisomal Biogenesis Factor 2 (PEX2)
kl605Bo01脂联素(ADP)多克隆抗体Polyclonal Antibody to Adiponectin (ADP)
kl605Ca01脂联素(ADP)多克隆抗体Polyclonal Antibody to Adiponectin (ADP)